 AVEO Oncology Nasdaq: AVEO today announced the closing of a tranched, 35 million debt facility with Hercules Capital, Inc. NYSE: HTGC and its affiliates. The new facility has a maturity of 36 months, extendable up to 48 months, and an interest-only period of 12 months, extendable up to 30 months upon the achievement of performance milestones related to the approval and commercialization of tivozanib. 